Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Fungal infection

Fungal infection

Subtypes of Fungal infection

Coccidioidomycosis 7 Blastomycosis 3 Histoplasmosis 3 Mucormycosis 3 Invasive candidiasis 2 Valley Fever 2 Vulvovaginal candidiasis 2 Aspergillosis 1 Mucorales infection 1 Mycetoma 1

28 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Fungal infection

29 trials tracked for Fungal infection: 16 in phase 3 or 4 and 5 with published results. The most-cited published study has 291 citations.

29Trials tracked
16Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 4 Phase 3 12 Phase 2 4 Phase 1 6 Other / NA 3
  1. Phase 3 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Completed · 291 cited
  2. Phase 3 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed · 108 cited
  3. Phase 3 Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Completed · 42 cited
  4. Phase 3 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole Completed · 38 cited
  5. Phase 3 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Completed · 20 cited
  6. Phase 4 A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed
Show 23 more trials
  1. Phase 4 Itraconazole Oral Absorption Completed
  2. Phase 4 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed
  3. Phase 4 Effect of Weight and/or Obesity on Caspofungin Drug Concentrations Completed
  4. Phase 3 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed
  5. Phase 3 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Completed
  6. Phase 3 A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066) Completed
  7. Phase 3 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) Completed
  8. Phase 3 Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis Completed
  9. Phase 3 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed
  10. Phase 3 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) Completed
  11. Phase 2 Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Completed
  12. Phase 2 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Completed
  13. Phase 2 Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Completed
  14. Phase 2 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options Completed
  15. Phase 1 Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615) Completed
  16. Phase 1 Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Completed
  17. Phase 1 Anidulafungin PK in Infants and Toddlers Completed
  18. Phase 1 Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) Completed
  19. Phase 1 Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers Completed
  20. Phase 1 Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520) Completed
  21. N/A A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation Completed
  22. N/A Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection Completed
  23. N/A Vfend Special Investigation For Prophylaxis Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Fungal infection: what the trials found

Several trials evaluated the efficacy and safety of various antifungal agents for fungal infections. Posaconazole was studied in multiple trials, demonstrating significant outcomes in mortality rates (p=<.0001) in one large study 5 and clinical responses at 4, 8, and 12 weeks in another 16. Other studies confirmed the use of Posaconazole across various phases [12, 17, 20].

Caspofungin acetate was evaluated in multiple trials [3, 8, 13, 14]. One study specifically noted a lower percentage of patients with proven or probable invasive fungal infections (3.1% vs 7.2%) and invasive aspergillosis (0.5% vs 3.1%) in the treatment arm 6.

Other established interventions include fast itraconazole tablets 1, prospective TDM arms 2, SUBA itraconazole, which showed fewer treatment-related adverse events and shorter hospitalizations compared to a comparator 7, Rezafungin for injection 9, isavuconazole 11, and Voriconazole 15.

A study on levofloxacin in a related context showed lower rates of bacteremia (21.9% vs 43.4%) and fever/febrile neutropenia compared to specific control groups 10.

Recent results — preliminary, needs further review

  • Olorofim was evaluated in a Phase 2 trial 18.
  • CD101 was evaluated in a Phase 2 trial 19.
  • Vorico Injection (Voriconazole) was evaluated in a Phase 1 trial 21.

For the clinician treating this condition

  • Posaconazole demonstrated significant mortality reduction (p=<.0001) and measurable clinical responses over a 12-week period.
  • Caspofungin acetate was associated with lower rates of invasive fungal infections and invasive aspergillosis in specific cohorts.
  • SUBA itraconazole showed a favorable safety profile with fewer treatment-related adverse events and shorter hospitalizations compared to alternatives.

AI synthesis of 13 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review on essential oils versus traditional antifungal drugs for fungal infections
Drug Pipeline Sys. Review
Narrative review on essential oils versus traditional antifungal drugs for fungal infections Nature's Shield: Essential Oils Fight Fungal Resistance
This narrative review synthesizes evidence on essential oils (EOs) and their compounds compared to traditional antifungal drugs for fungal i…
Essential oils from common plants can stop fungal infections more effectively and safely than many traditional medicines.
Frontiers Apr 19, 2026
Pooled analysis review of rezafungin versus caspofungin for candidemia and invasive candidiasis
Drug Pipeline
Pooled analysis review of rezafungin versus caspofungin for candidemia and invasive candidiasis Weekly Drug Clears Blood Fungus Faster Than Daily Treatment
This review synthesizes a pooled analysis of two randomized trials evaluating rezafungin versus caspofungin in adults with candidemia or inv…
A new weekly medication clears blood infections just as well as daily shots, offering hope for shorter care.
Apr 19, 2026
Observational study in Sudan finds few immune differences in mycetoma species
Infectious Disease
Observational study in Sudan finds few immune differences in mycetoma species Grains hide a secret immune trap in mycetoma
This research article describes an observational study of 11 patients with mycetoma in Sudan, analyzing immune protein distribution and cell…
In mycetoma, a shield of immune cells forms right next to the grain, blocking healing and trapping the disease inside the body.
medRxiv Apr 16, 2026
Review synthesizes fungal immune evasion mechanisms and emerging immunotherapies for invasive fungal infections
Infectious Disease Sys. Review
Review synthesizes fungal immune evasion mechanisms and emerging immunotherapies for invasive fungal infections Review explores how fungi evade immune systems and potential new treatment approaches
A narrative review synthesizes advances in understanding immune evasion by major fungal pathogens and immune dysregulation in immunocompromi…
Fungi like Candida and Aspergillus evade the immune system by hiding or forming biofilms, but new treatments could combine antifungal drugs …
Frontiers Apr 7, 2026
Regional analysis examines coccidioidomycosis incidence in California
Infectious Disease
Regional analysis examines coccidioidomycosis incidence in California Health officials report on Valley fever cases in California
An observational report analyzed coccidioidomycosis incidence in California.
California health officials released a regional analysis of Valley fever cases, providing an update on where this fungal infection has been …
CDC Apr 6, 2026
Case series describes COVID-19-associated Mucormycosis in Arkansas patients
Infectious Disease
Case series describes COVID-19-associated Mucormycosis in Arkansas patients What happens when COVID-19 patients in Arkansas develop a rare fungal infection?
A descriptive case series reported cases of COVID-19-associated Mucormycosis in Arkansas.
Doctors in Arkansas report that some patients recovering from COVID-19 also developed a rare and serious fungal infection called mucormycosi…
CDC Apr 6, 2026
Mucormycosis cases described in Honduras during the COVID-19 pandemic
Infectious Disease
Mucormycosis cases described in Honduras during the COVID-19 pandemic What happened to COVID-19 patients in Honduras with rare fungal infections?
A descriptive case series from Honduras reported mucormycosis cases occurring during the COVID-19 pandemic.
Doctors in Honduras reported rare black fungus infections in COVID-19 patients, prompting a warning for clinicians to watch for this aggress…
CDC Apr 6, 2026
Report highlights public awareness of invasive fungal diseases for treatment accuracy
Infectious Disease
Report highlights public awareness of invasive fungal diseases for treatment accuracy Report highlights importance of public awareness for serious fungal infections
A non-clinical report describes the concept that public awareness of invasive fungal diseases may prevent incorrect treatment and improve ou…
Public awareness of serious fungal infections can prevent incorrect treatment and improve health outcomes for those with weakened immune sys…
CDC Apr 6, 2026
Survey examines Valley fever awareness among California general population
Infectious Disease
Survey examines Valley fever awareness among California general population Survey examines public awareness of Valley fever in California
A survey assessed Valley fever awareness in California's general population.
A new survey checked how much people in California know about Valley fever, but the results haven't been shared yet.
CDC Apr 6, 2026
Surveillance report describes 2019 cases of coccidioidomycosis, histoplasmosis, and blastomycosis in the US
Infectious Disease
Surveillance report describes 2019 cases of coccidioidomycosis, histoplasmosis, and blastomycosis in the US CDC surveillance report describes cases of three fungal diseases in 2019
A national surveillance summary describes cases of coccidioidomycosis, histoplasmosis, and blastomycosis reported in the United States in 20…
A 2019 CDC report tracks three fungal diseases in the U.S., helping doctors understand where Valley fever, histoplasmosis, and blastomycosis…
CDC Apr 5, 2026
Blastomycosis outbreak reported among workers at a Michigan paper mill
Infectious Disease
Blastomycosis outbreak reported among workers at a Michigan paper mill Health officials investigate blastomycosis outbreak among Michigan paper mill workers
An outbreak investigation report describes a blastomycosis outbreak among workers at a paper mill in Michigan.
Michigan health officials investigate a blastomycosis outbreak among paper mill workers, prompting a look at fungal risks in the workplace.
CDC Apr 5, 2026
Observational report examines topical antifungal prescribing trends in Medicare Part D
Infectious Disease
Observational report examines topical antifungal prescribing trends in Medicare Part D How are doctors prescribing antifungal creams to older Americans?
An observational report examined topical antifungal prescribing trends among Medicare Part D beneficiaries in the United States.
A new report shows how doctors prescribe antifungal creams to older Americans enrolled in Medicare Part D.
CDC Apr 5, 2026

Questions about Fungal infection

Does having a fungal infection mean I have a bacterial infection in my lungs?

Having a fungal infection in your lungs does not automatically mean you have a bacterial infection, though both can occur together in certain conditions like HIV or COPD.

Full answer →